Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, with a filing date of July 15, 2019. The document serves as a transaction notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It details share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively reports on specific share transactions executed by insiders.
| Instrument | Transaction Date | Price | Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (GBP) | 2019-07-12 | £16.2695 | Various (e.g., 1,482.518 for CEO) | London Stock Exchange (XLON) |
| American Depositary Shares (USD) | 2019-07-12 | $40.6287 | Various (e.g., 729.935 for CEO Consumer Healthcare) | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position, operations, or strategy are reported in this filing. The document solely records routine acquisitions of shares by executives and their associates following the dividend payment date of July 11, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Investor Verification Checklist
- Verify the dividend reinvestment plan terms and the specific dividend payment date of July 11, 2019.
- Confirm the market price of GSK Ordinary Shares and ADSs on July 12, 2019, to validate the transaction prices of £16.2695 and $40.6287 respectively.
- Review the total volume of shares acquired by the Chief Executive Officer (Ms E Walmsley) and other senior executives to assess insider confidence levels.
- Check subsequent filings to ensure these transactions were reported in accordance with the company's insider trading policy.